Which incretin-based therapy has shown the greatest glucose-lowering efficacy and weight loss potential in trials?

Which incretin-based therapy has shown the greatest glucose-lowering efficacy and weight loss potential in trials?

• A. Semaglutide once weekly
• B. Liraglutide once daily
• C. Exenatide once weekly
• D. Tirzepatide once weekly

Answer: (D)

Tirzepatide combines effects on two incretin receptors, GIP and GLP-1, given weekly. That dual action enhances insulin secretion in a glucose-dependent way while also more robustly reducing appetite and promoting weight loss than GLP-1–only therapies. In large trials across diabetes and obesity populations, tirzepatide consistently produced the largest HbA1c reductions and the most substantial weight loss compared with GLP-1 receptor agonists such as those given weekly or daily. The additive/synergistic effect of stimulating both incretin pathways explains why this option shows the greatest glucose-lowering efficacy and weight loss potential in trials.

Tirzepatide combines effects on two incretin receptors, GIP and GLP-1, given weekly. That dual action enhances insulin secretion in a glucose-dependent way while also more robustly reducing appetite and promoting weight loss than GLP-1–only therapies. In large trials across diabetes and obesity populations, tirzepatide consistently produced the largest HbA1c reductions and the most substantial weight loss compared with GLP-1 receptor agonists such as those given weekly or daily. The additive/synergistic effect of stimulating both incretin pathways explains why this option shows the greatest glucose-lowering efficacy and weight loss potential in trials.